Mankind Pharma MANKIND
India-focused branded generics leader - No. 1 by prescription volume, strong in tier-2/3 towns, plus OTC brands and (since 2024) Bharat Serums & Vaccines
Mapped in 1 theme: Pharmaceuticals.
Where Mankind Pharma sits in the supply chain
Mankind Pharma appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › India branded formulations
OperatorOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 10,260 | 12,207 | 14,278 |
| Net profit | 1,942 | 2,011 | 1,938 |
Latest-year revenue ₹14,278 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Almost all revenue is domestic, so no US price-erosion or tariff exposure
- Deep rural/semi-urban distribution and top-10 brands (Manforce, Prega News, Moxikind) built at low marketing cost
- Bharat Serums & Vaccines acquisition adds women's health, critical care and biologics capability
Risks
- Bharat Serums deal (~₹13,600 Cr EV) was debt-funded - FY26 profit slipped on interest and amortisation despite 17% revenue growth
- Acute and mass-market mix is more exposed to NLEM price caps and trade-generic competition
- Integration execution on a large acquisition is new for the company
Common questions
What does Mankind Pharma do?
India-focused branded generics leader - No. 1 by prescription volume, strong in tier-2/3 towns, plus OTC brands and (since 2024) Bharat Serums & Vaccines.
Where does Mankind Pharma sit in the supply chain?
Mankind Pharma (NSE: MANKIND) is mapped in 1 supply-chain layer: India branded formulations (Pharmaceuticals).
Who are Mankind Pharma's peers?
In the India branded formulations layer of Pharmaceuticals: Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Alkem Laboratories, Abbott India, Eris Lifesciences, Cipla and 4 more.
What is Mankind Pharma's market cap and valuation?
As of 30 Oct 2026: market cap ₹1.03L Cr, P/E 44.3x, ROCE 13.5%, ROE 13.1%, dividend yield 0.04%.